Pre and post-treatment microPET/CT Study.

<p>(<b>A</b>) Biodistribution of ⁶⁴Cu-NOTA-bevacizumab in mice (n = 4 mice per group) bearing 786-O renal cell carcinoma tumors after treatment with RAD001 or vehicle. (<b>B</b>) Mice bearing 786-O renal cell carcinoma ear tumors were scanned at baseline following i.v. injection of 100 µCi ⁶⁴Cu-NOTA-bevacizumab (n = 4). RAD001 was then administered for 7 days and the scans repeated. There was a marked decreased in ⁶⁴Cu-NOTA-bevacizumab signal in the RAD001 compared to the vehicle control treated mouse. (<b>C</b>) Diminution of standard uptake value (SUV) in the RAD001 compared to vehicle treated mice.